Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

Y Collette (1) , Thomas Prébet (1) , A. Goubard (1) , José Adelaïde (1) , R Castellano (1) , N Carbuccia (1) , S Garnier (1) , A Guille (1) , C Arnoulet (1) , A Charbonier (1) , Mj Mozziconacci (1) , D Birnbaum (1) , M Chaffanet (1) , N Vey (1)

1 CRCM - Centre de Recherche en Cancérologie de Marseille

Tyrosine kinase inhibitor (TKI)-based targeted therapy has significantly modified the outcome for patients with chronic myeloid leukemia (CML) in chronic phase. However, resistance remains a major concern in blastic phase of CML and in Philadelphia chromosome positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Second- and third-generation TKIs have been developed to overcome resistance to first generation drugs, but selecting the appropriate drug has become a challenge. Various tests are available to determine a patient’s disease status in CML including the mechanisms of resistance when involved, but clinical experience is limited in ALL, especially those with poorly defined ABL1 rearrangements. Here, we report a case of ALL associated with a t(1;9)(q24;q34) RCSD1-ABL1 rearrangement. We show how ex vivo drug response profiling (DRP) may help choose among various therapeutic options.

Mots clés: BCR-ABL INHIBITOR; MYELOID-LEUKEMIA; RCSD1-ABL1; RESISTANCE; AP24534; FUSION

Domaines: Cancer

Y Collette, Thomas Prébet, A. Goubard, José Adelaïde, R Castellano, et al.. Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5 (e292), ⟨10.1038/bcj.2015.13⟩. ⟨hal-01218497⟩